Expert oncologists review data presented at recent conferences and discuss current multidisciplinary strategies for the treatment of patients with HR+/HER2- breast cancer.
September 26th 2023
Experts debate the utility of surgery on the primary tumor in patients with novel metastatic HR+/HER- breast cancer.
Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.